fig4

Figure 4. Potential cell surface proteins and their complements to be used in immunomodulation, immunotherapy, and targeted-drug delivery applications. t-SNARE/v-SNARE: target snap receptor/vesicle snap receptor; PS: phosphatidylserine; C1q: complement component 1q; SCARF-1: scavenger receptor class-F, member-1; Gp1b: glycoprotein-Ib; TSP-2: thrombospondin-2; SIRPα: signal regulatory protein α; CD: cluster of differentiation; ICAM: intercellular adhesion molecule; LFA-1: lymphocyte function-associated antigen-1; MAC-1: macrophage adhesion ligand-1; VLA: very late antigen; PAMP: pathogen associated molecular pattern; DAMP: damage-associated molecular pattern; PD-1/PD-2: programmed cell death protein-1/programmed cell death protein-2; PD-L1/PD-L2: programmed death-ligand-1/programmed death-ligand-2; CTLA-4: cytotoxic t-lymphocyte-associated protein-4; TRAIL: tumor necrosis factor-related apoptosis-inducing ligand; TNF: tumor necrosis factor; B7-H6: B7 homolog 6; MIC: MHC class I polypeptide-related sequence; H60: histocompatibility protein-60; NKp: natural cytotoxicity triggering receptor; NKG: natural killer cell granule protein; KIR: killer-cell immunoglobulin-like receptor; LIR: leukocyte immunoglobulin-like receptor; HMGβ1: high-mobility group protein β1; RAGE: receptor for advanced glycation end products